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Identifying and quantifying the role of risk factors with potential to modify 
multiple sclerosis (MS) disease course from onset to the emergence and 
evolution of the progressive phase, is of paramount importance for 
patients and clinicians in the optimum management of the condition1. 
Across online discussion boards and related social media settings, 
patients engage in ongoing dialog about which diets, exercise and other 
activities can empower them to live well and effectively manage their 
disease.  These discussions also influence the patient’s interaction with 
their physician as they ask for their provider’s perspective on which 
diet/exercise or other activity they should undertake. Sadly this patient-
physician dialogue is often challenging and unfruitful as the majority of 
studies evaluating areas such as diet, vitamin supplementation or 
exercise, tend to be either small or lacking in robust methodology. Thus 
while many factors are frequently cited as having an impact on disease 
course, few have the necessary evidence-base to support this 
contention. Furthermore clarity as to the importance of the role of such 
factors is essential in selecting out those that justify further evaluation in 
clinical trials, thus focusing effort and avoiding the expense of 
unnecessary studies.  
These issues are comprehensively addressed in the pair of systematic 
reviews carried out by Hempel and colleagues from RAND Corporation 
































































and United States Veterans Administration2,3. They focus specifically on 
fourteen risk factors in the context of progression or worsening which is 
particularly relevant, given the paucity of effective treatments for these 
forms of the disease4. In the first paper, the authors review all potential 
modifiable risk factors applying random meta-analysis models and 
GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) framework to assess the quality of evidence in 59 studies. 
The GRADE framework for prognostic factor research incorporates eight 
criteria including not only study limitations and cohort size but also 
inconsistency, indirectness, imprecision and publication bias5. 
The authors found that of fourteen risk factors studied, there was 
sufficient evidence to make definitive statements about only three of 
them; Lower Vitamin D levels were associated with higher EDSS scores 
and cigarette smokers had an increased risk of progression while, on the 
other side, there was no evidence of an association between disease 
progression and the use of epidural analgesics during childbirth. For the 
other eleven risk factors, which included diet, alcohol, exercise and 
trauma there was insufficient evidence to determine a firm and 
compelling relationship with progression.   
In the second systematic review, 37 trials of the effect of modifiable risk 
factor interventions on progression were reviewed. No clear beneficial 
































































effect from any risk factor was identified. The most striking and 
consistent finding was the poor quality of the trials of modifiable risk 
factors – a feature readily identified by the GRADE framework.  
The important and troubling messages from these papers are very clear 
and highly relevant to our aspiration to provide optimum care for persons 
with MS. The first and most concerning is the very poor quality of studies 
in this important area the majority of which were well below what would 
be regarded as acceptable and what we have come to expect in 
therapeutic trials. The second message is that there are factors, albeit 
only two, with a significant association with progression and therefore 
warrant well designed therapeutic trials. This applies most strongly to 
Vitamin D and although there are currently two studies underway, there 
is a case for considering additional trials. 
Overall, this is a very valuable body of work and if there are any 
criticisms to be made, perhaps the use of the term progression may be 
one. Here it applies to deterioration or worsening as a result of relapse 
activity or gradual deterioration as is seen in the progressive phase of 
MS. This use of the term progression runs contrary to the 
recommendations contained within the recent revision of the clinical 
course descriptors6 where we are encouraged to restrict the term 
progression to the gradual deterioration seen in progressive MS and use 
































































the term worsening when referring to deterioration as a sequelae to a 
relapse. 
Notwithstanding, the MS community would do well to take heed of and 
be guided by the findings of these systematic reviews. It is time we took 
the role of potentially modifiable factors more seriously and accorded 
their study the same rigour and attention that we so readily apply to 
therapeutic trials of disease modifying agents. While investment in such 
rigour will require energy, focus and importantly - financial resources, 
clarifying the role of modifiable factors in progression is essential to 
generate the evidence which will allow patients and physicians can have 
productive dialog about actions the patient can take to manage their 
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